SG11201504394TA - Solid unit with high fexofenadine content and process for the preparation thereof - Google Patents

Solid unit with high fexofenadine content and process for the preparation thereof

Info

Publication number
SG11201504394TA
SG11201504394TA SG11201504394TA SG11201504394TA SG11201504394TA SG 11201504394T A SG11201504394T A SG 11201504394TA SG 11201504394T A SG11201504394T A SG 11201504394TA SG 11201504394T A SG11201504394T A SG 11201504394TA SG 11201504394T A SG11201504394T A SG 11201504394TA
Authority
SG
Singapore
Prior art keywords
preparation
solid unit
fexofenadine
content
fexofenadine content
Prior art date
Application number
SG11201504394TA
Other languages
English (en)
Inventor
Baptiste Merillon
Jean-Yves Lanne
Marie Renouard
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47902228&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201504394T(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of SG11201504394TA publication Critical patent/SG11201504394TA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SG11201504394TA 2012-12-21 2013-12-20 Solid unit with high fexofenadine content and process for the preparation thereof SG11201504394TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1262647A FR2999937B1 (fr) 2012-12-21 2012-12-21 Unite solide a haute teneur en fexofenadine et son procede de preparation
PCT/EP2013/077752 WO2014096387A1 (en) 2012-12-21 2013-12-20 Solid unit with high fexofenadine content and process for the preparation thereof

Publications (1)

Publication Number Publication Date
SG11201504394TA true SG11201504394TA (en) 2015-07-30

Family

ID=47902228

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201504394TA SG11201504394TA (en) 2012-12-21 2013-12-20 Solid unit with high fexofenadine content and process for the preparation thereof

Country Status (25)

Country Link
US (1) US9757340B2 (ja)
EP (1) EP2934491B1 (ja)
JP (1) JP6276287B2 (ja)
KR (1) KR20150100725A (ja)
CN (1) CN105073101B (ja)
AR (1) AR094146A1 (ja)
AU (1) AU2013366512B2 (ja)
BR (1) BR112015014137B8 (ja)
CA (1) CA2895607A1 (ja)
CL (1) CL2015001681A1 (ja)
EA (1) EA030982B1 (ja)
ES (1) ES2625447T3 (ja)
FR (1) FR2999937B1 (ja)
HK (1) HK1211234A1 (ja)
HU (1) HUE032393T2 (ja)
IL (1) IL239267A0 (ja)
MX (1) MX360047B (ja)
PH (1) PH12015501377A1 (ja)
PL (1) PL2934491T3 (ja)
SG (1) SG11201504394TA (ja)
TN (1) TN2015000267A1 (ja)
TW (1) TWI624275B (ja)
UY (1) UY35235A (ja)
WO (1) WO2014096387A1 (ja)
ZA (1) ZA201504079B (ja)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2956011B1 (en) 2013-02-14 2018-03-28 Sanofi Chewable composition for oral administration and process for preparing thereof
WO2017073738A1 (ja) * 2015-10-29 2017-05-04 日本臓器製薬株式会社 フェキソフェナジンを有効成分とする錠剤
EP4119129A4 (en) * 2020-03-11 2024-01-24 Sawai Pharmaceutical Co., Ltd. GRANULES AND THEIR USE
WO2023145869A1 (ja) * 2022-01-31 2023-08-03 住友精化株式会社 製剤用組成物の製造方法及び製剤の製造方法
WO2023145871A1 (ja) * 2022-01-31 2023-08-03 住友精化株式会社 製剤用組成物の製造方法及び製剤の製造方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK164642C (da) * 1984-08-30 1992-12-14 Merrell Dow Pharma Farmaceutisk middel indeholdende terfenadin i form af en varmsmelte paafyldt paa kapsler
CN1044319C (zh) * 1984-08-30 1999-07-28 默里尔多药物公司 热熔融抗组胺组合物的制备方法
AU701042B2 (en) 1995-02-28 1999-01-21 Aventisub Llc Pharmaceutical composition for piperidinoalkanol compounds
US6723348B2 (en) * 2001-11-16 2004-04-20 Ethypharm Orodispersible tablets containing fexofenadine
ATE381350T1 (de) * 2003-03-07 2008-01-15 Ind Swift Ltd Geschmacklose, direkt verpressbare, schnelllösliche komplexe und ihre pharmazeutischen zusammensetzungen.
FR2959130A1 (fr) * 2010-04-21 2011-10-28 Sanofi Aventis Procede de preparation de compositions pharmaceutiques destinees a l'administration par voie orale comprenant un ou plusieurs principes actifs et les compositions les comprenant.
EP2956011B1 (en) 2013-02-14 2018-03-28 Sanofi Chewable composition for oral administration and process for preparing thereof

Also Published As

Publication number Publication date
TN2015000267A1 (en) 2016-10-03
EA030982B1 (ru) 2018-10-31
US9757340B2 (en) 2017-09-12
AR094146A1 (es) 2015-07-15
AU2013366512B2 (en) 2017-11-09
JP2016511223A (ja) 2016-04-14
BR112015014137A2 (pt) 2017-07-11
AU2013366512A1 (en) 2015-07-09
IL239267A0 (en) 2015-07-30
CN105073101A (zh) 2015-11-18
EA201591150A1 (ru) 2015-11-30
CL2015001681A1 (es) 2015-08-21
UY35235A (es) 2014-07-31
BR112015014137B8 (pt) 2023-01-24
MX2015008068A (es) 2016-04-25
HUE032393T2 (en) 2017-09-28
FR2999937A1 (fr) 2014-06-27
FR2999937B1 (fr) 2015-01-09
WO2014096387A1 (en) 2014-06-26
ES2625447T3 (es) 2017-07-19
HK1211234A1 (en) 2016-05-20
CA2895607A1 (en) 2014-06-26
KR20150100725A (ko) 2015-09-02
MX360047B (es) 2018-10-19
US20150313885A1 (en) 2015-11-05
EP2934491A1 (en) 2015-10-28
ZA201504079B (en) 2016-04-28
JP6276287B2 (ja) 2018-02-07
PH12015501377A1 (en) 2015-09-02
CN105073101B (zh) 2018-10-09
TW201431569A (zh) 2014-08-16
TWI624275B (zh) 2018-05-21
BR112015014137B1 (pt) 2022-12-13
EP2934491B1 (en) 2017-02-22
PL2934491T3 (pl) 2017-09-29

Similar Documents

Publication Publication Date Title
EP2932401A4 (en) CONTENT DISTRIBUTION CADRICAL
EP2867896A4 (en) RHYTHM OF CONTENT
SG11201404870YA (en) Process for the preparation of polypropylene with low ash content
EP2885662A4 (en) IMPROVED MATERIAL STUDY
EP2934454C0 (en) ANTI-DANDRUFF COMPOSITION
GB201104542D0 (en) Content provision
EP2808681A4 (en) breathalyser
SG11201405261TA (en) Bio-polyols for bio-lubricant and bio-polymer and methods for the preparation thereof
EP2898625A4 (en) CONSCIOUS CONTENT DISTRIBUTION OF CONTEXT
IL229684A (en) Screw
HK1204961A1 (en) Solid pharmaeutical preparation containing levothyroxine
HK1211234A1 (en) Solid unit with high fexofenadine content and process for the preparation thereof
EP2943893A4 (en) PROVISION OF ORGANIZED CONTENT
IL235805A (en) Pyrimidinyl-Diazaspiro compound and process for preparation
GB201205477D0 (en) Content distribution
IL229432A0 (en) Chondroitin sulfate domi-shark and a process for its preparation
EP2899254A4 (en) BIOCOMBUSTIBLE PRODUCT AND METHOD OF OBTAINING
GB201217004D0 (en) Improvements in resolving video content
HK1180202A1 (zh) 泡茶工藝及其專用泡茶裝置
GB201213778D0 (en) Process and dressng
PL398021A1 (pl) Nowa diacylo-sn-glicero-3-fosfocholina oraz sposób jej otrzymywania
PL398018A1 (pl) Nowa diacylo-sn-glicero-3-fosfocholina oraz sposób jej otrzymywania
GB201222736D0 (en) Composition and process
GB2501283B (en) Microbiological safety cabinets
ZA201308457B (en) Shark-like chondroitin sulphate and process for the preparation thereof